VividVisions. Legal performance marketing Log in

BioZorb marker leads
for plaintiff firms.

Hologic’s BioZorb implantable marker, used to mark soft tissue such as breast tissue for future procedures, was recalled in October 2024. Claims allege complications such as pain, infection, migration and erosion. We screen claimants against your firm’s criteria.

Discuss a campaign
Serving law firms nationwide

Summary of public information for law firms. Not legal advice.

Delivery models

Three ways to receive BioZorb cases.

The right model depends on your intake capacity and acquisition economics.

At the inquiry

Qualified leads

Claimants screened against your firm’s BioZorb criteria, delivered with their responses to your intake team or CRM.

For teams that handle follow-up and conversion.

Discuss qualified leads

At the conversation

Warm transfers

Screened claimants connected directly with your intake team during agreed hours and within your delivery caps.

For teams ready to take a live call.

How live transfers work

At the retainer

Signed retainers

For select programs, acquisition structured around qualified, completed e-signed retainers.

For firms seeking a retained-client model.

About retainer programs

The litigation · October 2026

What firms
should know now.

Litigation moves quickly. We confirm current status, and whether a program fits your firm’s strategy, before launch.

Sources
  1. Nov 2022

    First complaint filed

    A product liability complaint against Hologic was filed in Massachusetts state court. Complaints were later filed for approximately 200 plaintiffs, most in the U.S. District Court for the District of Massachusetts.

  2. Oct 2024

    Class I recall

    Hologic recalled all lots of unused BioZorb Markers, and the FDA classified the recall as Class I, its most serious type. The FDA lists 53,492 devices distributed between April 2019 and April 2024.

  3. Jan 2026

    Settlement executed

    Hologic executed a settlement agreement, with no admission of liability, subject to a participation threshold. If conditions are met, it will resolve the substantial majority of BioZorb cases.

Screening

Questions built
from your criteria.

These are the areas BioZorb screening typically covers. The exact questions and thresholds come from your firm.

Talk through your criteria
  1. Implant confirmation

    Whether a BioZorb marker was implanted, with the procedure date and facility, and whether records identify the device.

  2. Complications

    Reported problems such as pain, infection, rash, migration, erosion or seroma, and whether removal surgery was needed.

  3. Treatment & records

    The care received for complications and the records available to support the claim.

  4. Representation & settlement status

    Whether the claimant is already represented or already part of the existing settlement.

Questions

What firms ask
about BioZorb.

Answers specific to your program are part of the first conversation.

Is the BioZorb litigation still taking new claims?

Hologic executed a settlement in January 2026 intended to resolve the substantial majority of the roughly 200 pending cases, subject to conditions. Whether new claims fit your docket is your firm’s judgment; we confirm program availability with you before launch.

What complications has the FDA reported?

The FDA’s recall notice lists reported adverse events including pain, infection, rash, device migration, device erosion, seroma and discomfort.

How is BioZorb implantation confirmed?

Screening can ask about the procedure, its date and facility, and whether the claimant has records identifying the marker. Document requirements are set by your firm.

Can leads include consent documentation?

Where a program requires it, leads can be delivered with a TrustedForm or Jornaya certificate. Call recordings for transfers depend on program support and applicable consent requirements.

Sources

Public sources for this summary.

Summary of public information as of October 2026, for law firms evaluating case acquisition. It is not legal advice, and litigation status changes.

Start a conversation

Let’s look at
your next campaign.

Send the practice area, criteria and volume you have in mind. We’ll talk through the right delivery model and a sensible starting point.

Book a 30-minute intro call

Your inquiry is emailed to our team. This website does not store form entries. Please share business requirements only.

Campaign inquiry

Ready for your email app.

Review the details below. Nothing has been sent.

Open email app

If your email app doesn’t open, copy the inquiry and email info@vividvisions.marketing.

This website

Website privacy

When you send a campaign inquiry, the details you enter are emailed to the VividVisions team. This website does not store form entries. If sending fails, you can instead pass the inquiry to your own email application and choose whether to send it.

This website uses Vercel Web Analytics to count page views and see which pages are read. It does not use cookies or advertising pixels and does not identify individual visitors. Its fonts are served with the website. Hosting and email providers may process technical or message data under their own policies.

This notice covers this corporate website. Consumer campaign pages and claimant forms require separate disclosures appropriate to their data collection and consent processes.

Questions: info@vividvisions.marketing